180 Wealth Advisors LLC Grows Holdings in Organon & Co. $OGN

180 Wealth Advisors LLC raised its position in Organon & Co. (NYSE:OGN) by 77.7% during the second quarter, Holdings Channel.com reports. The firm owned 113,354 shares of the company’s stock after buying an additional 49,559 shares during the period. 180 Wealth Advisors LLC’s holdings in Organon & Co. were worth $1,097,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Douglas Lane & Associates LLC lifted its holdings in Organon & Co. by 19.0% in the 2nd quarter. Douglas Lane & Associates LLC now owns 315,952 shares of the company’s stock valued at $3,058,000 after purchasing an additional 50,393 shares in the last quarter. Triumph Capital Management lifted its holdings in Organon & Co. by 109.1% in the 2nd quarter. Triumph Capital Management now owns 90,342 shares of the company’s stock valued at $875,000 after purchasing an additional 47,127 shares in the last quarter. Sequoia Financial Advisors LLC lifted its holdings in Organon & Co. by 42.2% in the 1st quarter. Sequoia Financial Advisors LLC now owns 19,392 shares of the company’s stock valued at $289,000 after purchasing an additional 5,758 shares in the last quarter. M&T Bank Corp lifted its holdings in Organon & Co. by 3.4% in the 1st quarter. M&T Bank Corp now owns 55,990 shares of the company’s stock valued at $833,000 after purchasing an additional 1,854 shares in the last quarter. Finally, WBI Investments LLC purchased a new position in Organon & Co. in the 1st quarter valued at about $946,000. 77.43% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (d+)” rating on shares of Organon & Co. in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $17.33.

Organon & Co. Trading Up 1.3%

NYSE OGN opened at $9.17 on Friday. Organon & Co. has a 12 month low of $8.01 and a 12 month high of $19.05. The company has a 50-day moving average of $9.92 and a 200-day moving average of $9.91. The company has a debt-to-equity ratio of 11.98, a current ratio of 1.65 and a quick ratio of 1.13. The company has a market cap of $2.38 billion, a P/E ratio of 3.41, a P/E/G ratio of 0.82 and a beta of 0.63.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $1.00 EPS for the quarter, beating analysts’ consensus estimates of $0.94 by $0.06. Organon & Co. had a net margin of 11.15% and a return on equity of 163.88%. The company had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.55 billion. During the same quarter in the prior year, the company posted $1.12 EPS. The company’s quarterly revenue was down .8% compared to the same quarter last year. Organon & Co. has set its FY 2025 guidance at EPS. As a group, equities analysts predict that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 11th. Stockholders of record on Friday, August 15th were paid a dividend of $0.02 per share. The ex-dividend date of this dividend was Friday, August 15th. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.9%. Organon & Co.’s dividend payout ratio is currently 2.97%.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.